<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473248</url>
  </required_header>
  <id_info>
    <org_study_id>VNV-00552</org_study_id>
    <nct_id>NCT04473248</nct_id>
  </id_info>
  <brief_title>Spartan COVID-19 System: Evaluation of Clinical Sample Collection</brief_title>
  <official_title>Evaluation of Clinical Sample Collection Project: Spartan COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spartan Bioscience Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Humber River Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spartan Bioscience Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of various sample collection methods for use with the&#xD;
      Spartan COVID-19 System. It will compare the results from the Spartan COVID-19 System with&#xD;
      results that are obtained using a predicate lab-based COVID-19 test that uses a&#xD;
      nasopharyngeal swab sample. The goal is to determine which sample collection methods are most&#xD;
      effective in capturing SARS-CoV-2 virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once the subject is recruited,two nasopharyngeal swabs using the standard method will be&#xD;
      taken from the patient. Additionally, two nasal swab samples will be taken using the Spartan&#xD;
      COVID-19 swabs with an adjusted tip. All samples will be analyzed using the Spartan COVID-19&#xD;
      System.&#xD;
&#xD;
      The lab-based predicate test will be taken at the same time, with results reported back to&#xD;
      Spartan to be compared with results obtained from the Spartan COVID-19 System.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2020</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each Patient enrolle dint he study will experience the same modes of sample collection and sample analysis.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The results of the Spartan COVID-19 System tests will not be shared with the participant or the lab, but the lab results will be shared with Spartan once analysis of the Spartan System samples is complete.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Asses the % agreement between predicate results and Spartan COVID-19 results.</measure>
    <time_frame>Through study completion; anticipated to be less than 6 months.</time_frame>
    <description>The purpose of this study is to evaluate which method has the best % agreement between the lab-based predicate results and Spartan COVID-19 System results.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Method 1- Nasopharyngeal Swab in transfer liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A nasopharyngeal swab will inoculate a proprietary solution which will be transferred to the Spartan COVID-19 System for analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Method 2- Dipping of specialized swab in VTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A nasopharyngeal swab will inoculate VTM solution. A modified traditional Spartan Swab will be dipped into the inoculated VTM solution and then transferred to the Spartan COVID-19 System for analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Method 3: Direct input of VTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using the VTM from Method 2, pipette 10uL of VTM, inoculated with sample, into the Spartan COVID-19 System for analysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Method 4: Collection of nasal sample.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using a modified tip of the Spartan swab, a nasal sample will be taken from the patient and directly placed into the Spartan COVID-19 System for analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spartan COVID-19 System</intervention_name>
    <description>PCR analysis of patient samples using the Spartan COVID-19 System</description>
    <arm_group_label>Method 1- Nasopharyngeal Swab in transfer liquid</arm_group_label>
    <arm_group_label>Method 2- Dipping of specialized swab in VTM</arm_group_label>
    <arm_group_label>Method 3: Direct input of VTM</arm_group_label>
    <arm_group_label>Method 4: Collection of nasal sample.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must have tested positive for COVID-19 via the existing nucleic acid testing method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara Linseman, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Spartan Bioscience Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Univeristy of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

